Stocksigma LogoStocksigma Logo

Concord Biotech Board to Consider Q2 and H1 Results on 27th Oct'26

Concord Biotech Ltd announced that its Board of Directors will meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated

Concord Biotech Board to Consider Q2 and H1 Results on 27th Oct'26

Concord Biotech Ltd 路 Intimation 路 27 Oct 2026, 5:30 am

Concord Biotech Board to Consider Q2 and H1 Results on 27th Oct'26 Concord Biotech Ltd announced that its Board of Directors will meet on 27th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26, alongside the Limited Review Report from Statutory Auditors. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed for designated persons and their immediate relatives until 48 hours post the declaration of the financial results.

Original exchange filing (PDF)

More announcements from Concord Biotech Ltd

All Concord Biotech Ltd announcements